Ikena moves to next stage in urothelial carcinoma trial

 

Item 8.01

Other Events.

In April 2022, Ikena Oncology, Inc. (the “Company”) advanced to stage two of the nivolumab combination expansion cohort in the Phase 1b clinical trial of IK-175 (NCT04200963). The study is currently evaluating IK-175 in patients with advanced or metastatic urothelial carcinoma who have progressed on multiple prior lines of therapy, including checkpoint inhibitors. The expansion cohorts of the trial follow a Simon two stage statistical design that requires that a predefined threshold of antitumor activity measured by the RECIST 1.1 overall response rate (ORR) be reached in stage one before advancing to stage two. As previously disclosed, the monotherapy expansion cohort advanced to stage two in September 2021. The Company plans to submit the initial clinical data from this trial to an oncology conference in the second half of 2022.

https://www.streetinsider.com/SEC+Filings/Form+8-K+Ikena+Oncology%2C+Inc.+For%3A+Apr+06/19881286.html